Related Experiment Videos
Megestrol acetate in unresectable hepatocellular carcinoma
M Colleoni1, P Nelli, G Vicario
1Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy.
Aims And Background:
No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested.
Methods:
To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed.
Results:
Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding).
Conclusions:
The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.